Patents by Inventor Mercedes Alonso Cascon

Mercedes Alonso Cascon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
    Patent number: 9284296
    Abstract: The present invention relates to novel bipyridine sulfonamide derivatives of formula (I) and their use for the treatment and/or prophylaxis of a neurodegenerative disease or condition, particularly Alzheimers disease (AD), a cardiovascular disease or a pathology involving ischemia. Additionally, processes for preparing such derivatives and pharmaceutical compositions comprising them are provided.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: March 15, 2016
    Assignee: AUBERGINE PHARMACEUTICALS LLC
    Inventors: Francisco Palomo Nicolau, Jorge Sánchez-Quesada, Javier López Ogalla, Félix Hernández Juan, Javier Villasante Prieto, Miguel Medina Padilla, Ana Fuertes Huerta, Juan Manuel Dominguez Correa, Susana Herrero Santos, Mercedes Alonso Cascón
  • GSK-3 inhibitors
    Patent number: 8686042
    Abstract: The invention relates to urea derivatives of formula (I) as inhibitors of glycogen synthase kinase 3?, GSK-3, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which GSK-3 is involved, such as Alzheimer's disease or non-insulin dependent diabetes mellitus.
    Type: Grant
    Filed: July 28, 2006
    Date of Patent: April 1, 2014
    Assignee: Neuropharma, S.A.
    Inventors: Ana Martinez Gil, Miguel Medina Padilla, Mercedes Alonso Cascon, Ana Fuertes Huerta, Maria Luisa Navarro Rico, Maria Jose Perez Puerto, Ana Castro Morera, Ester Martin Aparicio
  • [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES
    Publication number: 20140011835
    Abstract: The present invention relates to a new family of [1,10]-phenantroline derivatives of formula (I), which are useful for the treatment or prophylaxis of a neurodegenerative or hematological disease or condition, their use as a medicament, especially for treating a neurodegenerative or hematological disease or condition, and a pharmaceutical composition comprising the compounds.
    Type: Application
    Filed: September 15, 2013
    Publication date: January 9, 2014
    Applicant: Noscira, S.A.
    Inventors: Ana MARTINEZ GIL, Ana Castro Morera, Miguel Medina Padilla, Jorge Sanchez-Quesada, Mercedes Alonso Cascon, Laura Rubio Arrieta, Esther Garcia Palomero, Paola Usan Egea
  • BIPYRIDINE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OR CONDITIONS
    Publication number: 20140005195
    Abstract: The present invention relates to novel bipyridine sulfonamide derivatives of formula (I) and their use for the treatment and/or prophylaxis of a neurodegenerative disease or condition, particularly Alzheimers disease (AD), a cardiovascular disease or a pathology involving ischemia. Additionally, processes for preparing such derivatives5 and pharmaceutical compositions comprising them are provided.
    Type: Application
    Filed: November 21, 2011
    Publication date: January 2, 2014
    Applicant: Noscira, S.A.
    Inventors: Francisco Palomo Nicolau, Jorge Sánchez-Quesada, Javier López Ogalla, Félix Hernández Juan, Javier Villasante Prieto, Miguel Medina Padilla, Ana Fuertes Huerta, Juan Manuel Dominguez Correa, Susan Herrero Santos, Mercedes Alonso Cascón
  • [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases
    Patent number: 8592446
    Abstract: The present invention relates to a new family of [1,10]-phenantroline derivatives of formula (I), which are useful for the treatment or profilaxis of a neurodegenerative or haematological disease or condition, their use as a medicament, especially for treating a treatment neurodegenerative or haematological disease or condition, and a pharmaceutical composition comprising the compounds.
    Type: Grant
    Filed: June 11, 2008
    Date of Patent: November 26, 2013
    Assignee: Noscira, S.A.
    Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Jorge Sanchez-Quesada, Mercedes Alonso Cascon, Laura Rubio Arrieta, Esther Garcia Palomero, Paola Usan Egea
  • GSK-3 inhibitors
    Patent number: 8158661
    Abstract: Provided are thiadiazolidine compounds of formula I wherein R1 is an organic group having at least 8 atoms selected from C or O, which is not linked directly to the N through a —C(O)— and comprising at least an aromatic ring, and their pharmaceutical compositions. These compounds are selective GSK-3 inhibitors and have improved bioavailability. They are useful for the treatment of GSK-3 mediated diseases, among others Alzheimer's disease, type II diabetes, depression and brain injury.
    Type: Grant
    Filed: April 22, 2009
    Date of Patent: April 17, 2012
    Assignee: Noscira, S.A.
    Inventors: Miguel Medina Padilla, Mercedes Alonso Cascon, Isabel Dorronsoro Diaz, Ana Martinez Gil, Gema Panizo Del Pliego, Ana Fuertes Huerta, Maria Jose Perez Puerto
  • TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER
    Publication number: 20110306631
    Abstract: The present invention relates to a new family of triple substituted phenantroline derivatives of formula (I), which are useful for the treatment or profilaxis of a neurodegenerative or haematological disease or condition or cancer, their use as a medicament, especially for treating a neurodegenerative or haematological disease or condition or cancer, and a pharmaceutical composition comprising the compounds.
    Type: Application
    Filed: December 10, 2009
    Publication date: December 15, 2011
    Applicant: NOSCIRA, S.A.
    Inventors: Miguel Medina Padilla, Ana Castro Morera, Jorge Sánchez-Quesada, Esther García Palomero, Mercedes Alonso Cascón, Susana Herrero Santos, Marta Vela Ruíz, Paola Usán Egea, Ana Luisa Rodríguez Villanueva
  • Use of collismycin and derivatives thereof as oxidative stress inhibitors
    Patent number: 8067441
    Abstract: The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment of oxidative stress-induced diseases or conditions, especially neurodegenerative diseases, such as Alzheimer's Disease and Parkinson's Disease.
    Type: Grant
    Filed: July 28, 2006
    Date of Patent: November 29, 2011
    Assignees: Neuropharma, S.A., Instituto Biomar, S.A.
    Inventors: Ana Martinez Gil, Paola Usan Egea, Miguel Medina Padilla, Esther Garcia Palomero, Julia Perez Baz, Rosa Isabel Fernandez Chimeno, Antonio Medarde Fernandez, Librada Maria Canedo Hernandez, Francisco Romero Millan, Ana Castro Morera, Mercedes Alonso Cascon, Jorge Sanchez Quesada
  • N-(2-THIAZOLYL)-AMIDE DERIVATIVES FOR THE TREATMENT OF OBESITY, DIABETES AND CARDIOVASCULAR DISEASES
    Publication number: 20110213000
    Abstract: The invention relates to the use of a compound of formula (I): its pharmaceutically acceptable salts, prodrugs and/or solvates, in the preparation of a medicinal product for the treatment of a disease presenting altered adiponectin levels or in which it is necessary to alter the adiponectin protein levels.
    Type: Application
    Filed: August 1, 2008
    Publication date: September 1, 2011
    Applicant: ZELTIA, S.A.
    Inventors: Ana Martínez Gil, Mercedes Alonso Cascón, Gema Santamaría Núñez, Marta Martínez Díez, Javier López Ogalla
  • [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES
    Publication number: 20100240692
    Abstract: The present invention relates to a new family of [1,10]-phenantroline derivatives of formula (I), which are useful for the treatment or profilaxis of a neurodegenerative or haematological disease or condition, their use as a medicament, especially for treating a treatment neurodegenerative or haematological disease or condition, and a pharmaceutical composition comprising the compounds.
    Type: Application
    Filed: June 11, 2008
    Publication date: September 23, 2010
    Applicant: NOSCIRA, S.A.
    Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Jorge Sanchez-Quesada, Mercedes Alonso Cascon, Laura Rubio Arrieta, Esther Garcia Palomero, Paola Usan Egea
  • Enzyme inhibitors
    Patent number: 7781463
    Abstract: Compounds of general formula (I): where A, E, G, X, Y and the bond - - - take various meanings are of use in the preparation of a pharmaceutical formulation, for example in the treatment of a disease in which GSK-3 is involved, including Alzheimer's disease or the non-dependent insulin diabetes mellitus, or hyperproliferative disease such as cancer, displasias or metaplasias of tissue, psoriasis, arteriosclerosis or restenosis.
    Type: Grant
    Filed: April 20, 2007
    Date of Patent: August 24, 2010
    Assignees: Consejo Superior de Investigaciones Cientificas, Universidad Autonoma de Madrid (UAM)
    Inventors: Ana Martinez Gil, Ana Castro Morera, Maria Concepcion Martin Perez, Mercedes Alonso Cascon, Isabel Dorronsoro Diaz, Francisco Jose Moreno Munoz, Francisco Wandosell Jurado
  • USE OF COLLISMYCIN AND DERIVATIVES THEREOF AS OXIDATIVE STRESS INHIBITORS
    Publication number: 20100048635
    Abstract: The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment and/or prevention of oxidative stress-induced diseases or conditions, especially neurodegenerative diseases, such as Alzheimer's Disease and Parkinson's Disease.
    Type: Application
    Filed: July 28, 2006
    Publication date: February 25, 2010
    Applicants: Neuropharma, S.A., Instituto Biomar, S.A.
    Inventors: Ana Martinez Gil, Paola Egea, Miguel Medina Padilla, Esther Palomero, Julia Perez Baz, Rosa Fernandez Chimeno, Antonio Medarde Fernandez, Librada Canedo Hernandez, Francisco Romero Millan, Ana Castro Morera, Mercedes Alonso Cascon, Jorge Sanchez Quesada
  • Enzyme inhibitors
    Patent number: 7666885
    Abstract: Compounds of general formula (I): where A, E, G, X, Y and the bond - - - take various meanings are of use in the preparation of a pharmaceutical formulation, for example in the treatment of a disease in which GSK-3 is involved, including Alzheimer's disease or the non-dependent insulin diabetes mellitus, or hyperproliferative disease such as cancer, displasias or metaplasias of tissue, psoriasis, arteriosclerosis or restenosis.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: February 23, 2010
    Assignees: Consejo Superior de Investigaciones Cientificas, Universidad Autonoma de Madrid (UAM)
    Inventors: Ana Gil Martinez, Ana Castro Morera, Maria Concepcion Martin Perez, Mercedes Alonso Cascon, Isabel Dorronsoro Diaz, Francisco Jose Moreno Munoz, Francisco Wandosell Jurado
  • GSK-3 Inhibitors
    Publication number: 20090233971
    Abstract: Provided are thiadiazolidine compounds of formula I wherein R1 is an organic group having at least 8 atoms selected from C or O, which is not linked directly to the N through a —C(O)— and comprising at least an aromatic ring, and their pharmaceutical compositions. These compounds are selective GSK-3 inhibitors and have improved bioavailability. They are useful for the treatment of GSK-3 mediated diseases, among others Alzheimer's disease, type II diabetes, depression and brain injury.
    Type: Application
    Filed: April 22, 2009
    Publication date: September 17, 2009
    Applicant: Noscira, S.A.
    Inventors: Miguel Medina Padilla, Mercedes Alonso Cascon, Isabel Dorronsoro Diaz, Ana Martinez Gil, Gema Panizo del Pliego, Ana Fuertes Huerta, Maria Jose Perez Puerto
  • N-(2-THIAZOLYL)-AMIDE DERIVATIVES AS GSK-3 INHIBITORS
    Publication number: 20090221647
    Abstract: The present invention relates to the use of N-(2-thiazolyl)-amide derivatives of formula (I), for the treatment and/or prophylaxis of a disease in which glycogen synthase kinase 3 (GSK-3) is involved, especially neurodegenerative diseases, such as Alzheimer's disease, or non-insulin dependent diabetes mellitus.
    Type: Application
    Filed: April 27, 2007
    Publication date: September 3, 2009
    Applicant: NOSCIRA, S.A.
    Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Ester Martin Aparicio, Mercedes Alonso Cascon, Ana Fuertes Huerta, Maria Luisa Navarro Rico, Maria Jose Perez Puerto, Maria Del Monte Millan
  • N-(2-THIAZOLYL)-AMIDE DERIVATIVES AS GSK-3 INHIBITORS
    Publication number: 20090192204
    Abstract: The present invention relates to the use of N-(2-thiazolyl)-amide derivatives of formula (I) for the treatment and/or prophylaxis of a disease in which glycogen synthase kinase 3 (GSK-3) is involved, especially neurodegenerative diseases, such as Alzheimer's disease, or non-insulin dependent diabetes mellitus.
    Type: Application
    Filed: April 27, 2007
    Publication date: July 30, 2009
    Applicant: NOSCIRA, S.A.
    Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Ester Martin Aparicio, Mercedes Alonso Cascon, Ana Fuertes Huerta, Maria Luisa Navarro Rico, Maria Jose Perez Puerto, Maria Del Monte Millan
  • GSK-3 INHIBITORS
    Publication number: 20090124686
    Abstract: The invention relates to urea derivatives of formula (I) as inhibitors of glycogen synthase kinase 3?, GSK-3, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which GSK-3 is involved, such as Alzheimer's disease or non-insulin dependent diabetes mellitus.
    Type: Application
    Filed: July 28, 2006
    Publication date: May 14, 2009
    Applicant: NEUROPHARMA, S.A.
    Inventors: Ana Martinez Gil, Miguel Medina Padilla, Mercedes Alonso Cascon, Ana Fuertes Huerta, Maria Luisa Navarro Rico, Maria Jose Perez Puerto, Ana Castro Morera, Ester Martin Aparicio
  • GSK-3 inhibitors
    Patent number: 7531561
    Abstract: Provided are thiadiazolidine compounds of formula I wherein R1 is an organic group having at least 8 atoms selected from C or O, which is not linked directly to the N through a —C(O)— and comprising at least an aromatic ring, and their pharmaceutical compositions. These compounds are selective GSK-3 inhibitors and have improved bioavailability. They are useful for the treatment of GSK-3 mediated diseases, among others Alzheimer's disease, type II diabetes, depression and brain injury.
    Type: Grant
    Filed: April 5, 2005
    Date of Patent: May 12, 2009
    Assignee: Noscira, S.A.
    Inventors: Miguel Medina Padilla, Mercedes Alonso Cascón, Isabel Dorronsoro Díaz, Ana Martínez Gil, Gema Panizo del Pliego, Ana Fuertes Huerta, María José Pérez Puerto
  • Use of Collismycin and Derivatives Thereof as Oxidative Stress Inhibitors
    Publication number: 20080275088
    Abstract: The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment and/or prevention of oxidative stress-induced diseases or conditions, especially neurodegenerative diseases, such as Alzheimer's Disease and Parkinson's Disease.
    Type: Application
    Filed: July 28, 2006
    Publication date: November 6, 2008
    Applicants: NEUROPHARMA, S.A., INSTITUTO BIOMAR, S.A.
    Inventors: Ana Martinez Gil, Paola Usan Egea, Miguel Medina Padilla, Esther Garcia Palomero, Julia Perez Baz, Rosa Isabel Fernandez Chimeno, Antonio Medarde Fernandez, Librada Maria Canedo Hernandez, Francisco Romero Millan, Ana Castro Morera, Mercedes Alonso Cascon, Jorge Sanchez Quesada
  • Use Of Heterocyclic Compounds As Neurogenic Agents
    Publication number: 20080153886
    Abstract: The invention relates to the use of heterocyclic compounds in the preparation of a medicament for regenerating damaged neuronal tissue. According to a preferred embodiment, formula I compounds are used to produce a medicament for regenerating neuronal tissue in pathologies or conditions that involve neuronal damage or death in the central nervous system or peripheral nervous system.
    Type: Application
    Filed: February 10, 2006
    Publication date: June 26, 2008
    Applicant: NEUROPHARMA, S.A.
    Inventors: Ana Martinez Gil, Rosario De Luna Medina, Ana Perez Castillo, Mercedes Alonso Cascon